---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-25-000048"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:11:07.062121+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q2 2025 revenue $174.4M, GAAP EPS $0.64; BAQSIMI sales up 21%

## Summary
- Net revenues $174.4M vs $182.4M YoY; GAAP net income $31.0M ($0.64 diluted EPS).
- Adjusted non-GAAP net income $40.9M ($0.85 diluted EPS) vs $48.7M ($0.94) YoY.
- BAQSIMI sales increased 21% YoY, cited as key revenue driver.
- Announced multi-year plan to quadruple manufacturing capacity at Rancho Cucamonga HQ.

## SEC filing metadata
- accession: 0001297184-25-000048
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718425000048/0001297184-25-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718425000048/amph-20250807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-25-000048
- JSON: https://secwatch.observer/filing/0001297184-25-000048.json
- Plain text: https://secwatch.observer/filing/0001297184-25-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.